SCHEMBL14636700

SCHEMBL14636700

CNC(=O)c1cccc(-c2cnc(Cl)o2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK8 P49336 1/20 0.50
HDAC8 Q9BY41 1/20 0.45
HDAC6 Q9UBN7 1/20 0.45
FYN P06241 4/20 0.45
VCP P55072 1/20 0.44
NR4A2 P43354 1/20 0.44
MAP4K4 O95819 1/20 0.44
CRBN Q96SW2 1/20 0.43
CYP17A1 P05093 1/20 0.43
CYP3A4 P08684 1/20 0.43
NR1H2 P55055 1/20 0.43
NR1H3 Q13133 1/20 0.43
BAZ2B Q9UIF8 1/20 0.43
FGFR1 P11362 1/20 0.42
FGFR3 P22607 1/20 0.42
PIP5K1C O60331 1/20 0.42
PIK3CA P42336 1/20 0.42
KDM5A P29375 1/20 0.41
KDM4C Q9H3R0 1/20 0.41
KDM5B Q9UGL1 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15115343 0.85 CDK8 (0.51) CDK8HDAC8HDAC6FYNVCP
SCHEMBL14637938 0.84 FAAH (0.55) CDK8VCPFAAH
SCHEMBL14638292 0.82 FAAH (0.53) CDK8FYNVCPMAP4K4FGFR1
SCHEMBL22280602 0.79 SMN1; SMN2 (0.59) VCPFAAH
SCHEMBL22280424 0.76 TP53 (0.47) FAAH
SCHEMBL21303774 0.76 VCP (0.62) CDK8VCP
SCHEMBL13702375 0.75 HDAC8 (0.68) CDK8HDAC8HDAC6FYNNR4A2
SCHEMBL13702383 0.75 NPC1 (0.52) CDK8HDAC8HDAC6FYNMAP4K4
SCHEMBL21303859 0.74 CDK8 (0.42) CDK8HDAC8HDAC6FYNVCP
SCHEMBL14637548 0.74 NQO2 (0.45) CYP3A4FAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8815909-B2 Diaminocyclohexane compounds and uses thereof BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-26 US disclosed
US-8815909-B2 Diaminocyclohexane compounds and uses thereof BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-26 US disclosed
US-8815909-B2 Diaminocyclohexane compounds and uses thereof BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-26 US disclosed
US-20130184284-A1 DIAMINOCYCLOHEXANE COMPOUNDS AND USES THEREOF BRISTOL-MYERS SQUIBB COMPANY 2013-07-18 US disclosed
US-20130184284-A1 DIAMINOCYCLOHEXANE COMPOUNDS AND USES THEREOF BRISTOL-MYERS SQUIBB COMPANY 2013-07-18 US disclosed
US-20130184284-A1 DIAMINOCYCLOHEXANE COMPOUNDS AND USES THEREOF BRISTOL-MYERS SQUIBB COMPANY 2013-07-18 US disclosed
WO-2013012827-A1 DIAMINOCYCLOHEXANE COMPOUNDS AND USES THEREOF BRISTOL-MYERS SQUIBB COMPANY (US) 2013-01-24 WO disclosed
WO-2013012827-A1 DIAMINOCYCLOHEXANE COMPOUNDS AND USES THEREOF BRISTOL-MYERS SQUIBB COMPANY (US) 2013-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130184284-A1 DIAMINOCYCLOHEXANE COMPOUNDS AND USES THEREOF NPY4R, NPY2R, NPY1R CDK8 3545/4885HDAC8 1770/4885HDAC6 1926/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.